Milestone Scientific (MLSS) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 14, 2019
Document Information [Line Items]
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Entity Central Index Key	0000855683
Trading Symbol	mlss
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		47,490,155
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,337,593	$ 743,429
Accounts receivable, net	1,658,919	1,978,456
Accounts receivable, related party, net		100,000
Prepaid expenses and other current assets	406,563	414,541
Deferred cost, related party		50,000
Inventories, net	1,270,480	1,921,051
Advances on contracts	530,114	648,783
Operating lease-right of use assets	92,830
Total current assets	6,296,499	5,856,260
Furniture, fixtures and equipment, net	65,668	82,557
Patents, net	408,767	435,273
Other assets	17,355	26,878
Total assets	6,788,289	6,400,968
Current liabilities:
Accounts payable	1,192,823	1,205,396
Accounts payable, related party	1,283,367	1,663,849
Accrued expenses and other payables	1,464,846	1,481,715
Accrued expenses, related party	125,428
Operating lease liabilities-current	92,830
Deferred profit, related party	372,700	421,800
Deferred revenue, related party		100,000
Derivative liability	1,418,863
Total current liabilities	5,950,857	4,872,760
Total liabilities	5,950,857	4,872,760
Commitments and contingencies
Stockholders’ equity
Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, 0 and 7,000 shares issued and outstanding as of June 30, 2019 and December 31, 2018.		7
Common stock, par value $.001; authorized 50,000,000 shares; 47,132,220 shares issued, 0 shares to be issued and 47,098,886 shares outstanding as of June 30, 2019 ; 33,859,034 shares issued, 2,470,565 shares to be issued and 33,825,701 shares outstanding as of December 31, 2018;	47,132	36,330
Additional paid in capital	89,559,585	88,414,718
Accumulated deficit	(87,823,965)	(85,999,929)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific Inc. stockholders' equity	871,236	1,539,610
Noncontrolling interest	(33,804)	(11,402)
Total stockholders’ equity	837,432	1,528,208
Total liabilities and stockholders’ equity	$ 6,788,289	$ 6,400,968

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)		$ 0.001
Preferred stock, shares authorized (in shares)		5,000,000
Preferred stock, shares issued (in shares)		7,000
Preferred stock, shares outstanding (in shares)		7,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	47,132,220	33,859,034
Common stock, shares to be issued (in shares)	0	2,470,565
Common stock, shares outstanding (in shares)	47,098,886	33,825,701
Treasury stock, at cost, shares (in shares)	33,333	33,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Product sales, net	$ 2,257,851	$ 2,428,498	$ 4,173,759	$ 4,234,103
Cost of products sold	752,183	1,021,573	1,370,876	1,584,250
Gross profit	1,505,668	1,406,925	2,802,883	2,649,853
Selling, general and administrative expenses	2,517,970	2,821,837	4,627,023	5,840,601
Research and development expenses	95,529	9,775	101,875	235,592
Total operating expenses	2,613,499	2,831,612	4,728,898	6,076,193
Loss from operations	(1,107,831)	(1,424,687)	(1,926,015)	(3,426,340)
Other expenses	(2,563)	(1,756)	(4,825)	(3,457)
Interest income	188	1,926	1,207	4,590
Change in fair value of derivative liability	12,462		52,722
Loss before provision for income taxes and net losses of equity investments	(1,097,744)	(1,424,517)	(1,876,911)	(3,425,207)
Provision for income taxes	(14,163)	(4,075)	(18,627)	(15,538)
Loss before equity in net earnings (losses) of equity investments	(1,111,907)	(1,428,592)	(1,895,538)	(3,440,745)
Income from earnings on China joint venture	(58,664)	(78,591)	(49,100)	(115,374)
Net loss	(1,053,243)	(1,350,001)	(1,846,437)	(3,325,371)
Net loss attributable to noncontrolling interests	11,959	6,994	22,402	108,657
Net loss attributable to Milestone Scientific Inc.	$ (1,041,284)	$ (1,343,007)	$ (1,824,036)	$ (3,216,714)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.04)	$ (0.09)
Diluted (in dollars per share)	$ (0.02)	$ (0.04)	$ (0.04)	$ (0.09)
Weighted average shares outstanding and to be issued—
Basic (in shares)	45,366,237	35,297,906	41,904,581	34,939,306
Diluted (in shares)	45,366,237	35,297,906	41,904,581	34,939,306

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Consultant [Member]Common Stock [Member]	Consultant [Member]Additional Paid-in Capital [Member]	Consultant [Member]	Board of Directors [Member]Common Stock [Member]	Board of Directors [Member]Additional Paid-in Capital [Member]	Board of Directors [Member]	Public Offering [Member]Common Stock [Member]	Public Offering [Member]Additional Paid-in Capital [Member]	Public Offering [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017													7,000	34,592,818
Balance at Dec. 31, 2017													$ 7	$ 34,593	$ 86,689,084	$ (78,568,284)	$ 256,744	$ (911,516)	$ 7,500,628
Stock based compensation															86,809				86,809
Common stock to be issued to employees for bonuses (in shares)														323,076
Common stock to be issued to employees for bonuses														$ 323	339,177				339,500
Net loss
Common stock for Asset Acquisition																(1,873,707)	(101,663)		(1,975,370)
Balance (in shares) at Mar. 31, 2018													7,000	34,915,894
Balance at Mar. 31, 2018													$ 7	$ 34,916	87,115,070	(80,441,991)	155,081	(911,516)	5,951,567
Balance (in shares) at Dec. 31, 2017													7,000	34,592,818
Balance at Dec. 31, 2017													$ 7	$ 34,593	86,689,084	(78,568,284)	256,744	(911,516)	7,500,628
Net loss																			(3,325,371)
Balance (in shares) at Jun. 30, 2018													7,000	35,573,473
Balance at Jun. 30, 2018													$ 7	$ 35,571	87,832,358	(81,784,998)	148,087	(911,516)	5,319,509
Balance (in shares) at Mar. 31, 2018													7,000	34,915,894
Balance at Mar. 31, 2018													$ 7	$ 34,916	87,115,070	(80,441,991)	155,081	(911,516)	5,951,567
Stock based compensation															84,092				84,092
Common stock to be issued to employees for bonuses (in shares)														79,307
Common stock to be issued to employees for bonuses														$ 79	59,921				60,000
Common stock to be issued for services (in shares)	296,046
Common stock to be issued for services	$ 294	$ 249,455	$ 249,749
Common stock to be issued to employee for compensation (in shares)														37,267
Common stock to be issued to employee for compensation														$ 37	37,463				37,500
Net loss																(1,343,007)	(6,994)		(1,350,001)
Common stock for Asset Acquisition (in shares)														244,959
Common stock for Asset Acquisition														$ 245	286,357				286,602
Balance (in shares) at Jun. 30, 2018													7,000	35,573,473
Balance at Jun. 30, 2018													$ 7	$ 35,571	87,832,358	(81,784,998)	148,087	(911,516)	5,319,509
Balance (in shares) at Dec. 31, 2018													7,000	36,329,600
Balance at Dec. 31, 2018													$ 7	$ 36,330	88,414,718	(85,999,929)	(11,402)	(911,516)	1,528,208
Stock based compensation															56,988				56,988
Common stock to be issued to employees for bonuses (in shares)														175,715
Common stock to be issued to employees for bonuses														$ 175	61,325				61,500
Common stock to be issued for services (in shares)	118,115			20,588
Common stock to be issued for services	$ 118	39,882	40,000	$ 21	$ 6,979	$ 7,000
Common stock to be issued to employee for compensation (in shares)														22,727
Common stock to be issued to employee for compensation														$ 23	7,477				7,500
Common stock issued in public offering (in shares)							6,282,400			714,286
Common stock issued in public offering							$ 6,281	$ 1,968,265	$ 1,974,546	$ 714	$ 249,286	$ 250,000
Reclassification of warrants and Shares to be issued to derivative liability (Note 8)															(406,045)				(406,045)
Net loss																(782,752)	(10,443)		(793,195)
Balance (in shares) at Mar. 31, 2019													7,000	43,663,431
Balance at Mar. 31, 2019													$ 7	$ 43,662	90,398,875	(86,782,681)	(21,845)	(911,516)	2,726,502
Balance (in shares) at Dec. 31, 2018													7,000	36,329,600
Balance at Dec. 31, 2018													$ 7	$ 36,330	88,414,718	(85,999,929)	(11,402)	(911,516)	1,528,208
Net loss																			(1,846,437)
Balance (in shares) at Jun. 30, 2019														47,132,220
Balance at Jun. 30, 2019														$ 47,132	89,559,585	(87,823,965)	(33,804)	(911,516)	837,432
Balance (in shares) at Mar. 31, 2019													7,000	43,663,431
Balance at Mar. 31, 2019													$ 7	$ 43,662	90,398,875	(86,782,681)	(21,845)	(911,516)	2,726,502
Stock based compensation															44,712				44,712
Common stock to be issued for services (in shares)	265,140			82,442
Common stock to be issued for services	$ 265	$ 139,735	$ 140,000	$ 82	$ 29,918	$ 30,000
Common stock to be issued to employee for compensation (in shares)														41,667
Common stock to be issued to employee for compensation														$ 42	14,958				15,000
Reclassification of warrants and Shares to be issued to derivative liability (Note 8)														$ (2,902)	(1,062,637)				(1,065,539)
Net loss																(1,041,284)	(11,959)		(1,053,243)
Conversion of Preferred Shares to Common Stock (Mandatory) (in shares)													(7,000)	5,982,906
Conversion of Preferred Shares to Common Stock (Mandatory)													$ (7)	$ 5,983	(5,976)
Reclassification of warrants and Shares to be issued to derivative liability (Note 8) (in shares)														(2,903,366)
Balance (in shares) at Jun. 30, 2019														47,132,220
Balance at Jun. 30, 2019														$ 47,132	$ 89,559,585	$ (87,823,965)	$ (33,804)	$ (911,516)	$ 837,432

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (1,846,437)	$ (3,325,371)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	24,993	40,762
Amortization of patents	26,506	469,356
Stock compensation	101,700	170,901
Income from earnings on China joint venture	(49,100)	(115,374)
Inventory reserve	(2,061)	290,349
Change in fair value of derivative liability	(52,722)
Amortization of right-of-use assets	79,109
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	319,537	(304,632)
Decrease (increase) in accounts receivable, related party	100,000	(1,092,540)
Decrease in other receivables	9,523
Decrease in inventories	652,631	778,530
Decrease (increase) in advances on contracts	118,669	(164,590)
Decrease (increase) in prepaid expenses and other current assets	7,978	(48,343)
(Decrease) increase in accounts payable	(12,573)	511,632
(Decrease) increase in accounts payable, related party	(380,482)	243,360
Increase (decrease) in deferred cost, related party	50,000	(686,365)
Increase in accrued expenses	284,128	623,014
Increase in accrued expenses, related party	125,428
(Decrease) increase in deferred revenue, related party	(99,997)	1,092,540
Decrease in operating lease-right of use asset	(79,109)
Net cash used in operating activities	(622,279)	(1,516,771)
Cash flows from investing activities:
Purchase of intangible assets		(4,531)
Purchase of property and equipment	(8,104)
Net cash used in investing activities	(8,104)	(4,531)
Cash flows from financing activities:
(Payments for) financing transaction		(250,000)
Net proceeds from Public Placement Offering	1,974,547
Net proceeds from Private Placement Offering	250,000
Net cash provided by financing activities	2,224,547	(250,000)
Net increase (decrease) in cash and cash equivalents	1,594,164	(1,771,302)
Cash and cash equivalents at beginning of period	743,429	2,636,956
Cash and cash equivalents at end of period	2,337,593	865,654
Supplemental disclosure of cash flow information:
Shares issued to employee for bonuses	61,500	399,500
Shares issue to board of directors for services rendered	37,000
Shares issued to employees for compensation	22,500
Shares issued to consultants in lieu of cash payments	180,000	249,749
Common stock issued for asset acquisition		286,602
Sale of Milestone China share, financing transaction		(1,400,000)
Initial recognition of operating lease-right of use assets	(166,292)
Initial recognition of operating lease right to used liabilities	166,292
Derivative liability for shares over allotment	$ 1,471,585

Note 1 - Organization and Busin

Note 1 - Organization and Business	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia System®; and The Wand ®. Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand® CompuDent®, STA Single Tooth Anesthesia System® CompuMed®. CompuDent® CompuMed® 60 During 2016, 510 CompuFlo June 2017, CompuFlo five In December 2016, 510 not 510 510 2019, In November 2018, not 1003 December 20, 2018, 1003 May 20, 2020. January 24, 2019, not 1003 In February 2019, $2.0 5,715,000 1,428,750 5 $0.50. $198,000 567,400 141,850 Also, in February 2019, $250,000 714,286 178,571 Bp4 Bp4’s 5 $0.50.

Note 2 - Going Concern and Liqu

Note 2 - Going Concern and Liquidity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one June 30, 2019 $2.3 not 12 Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever. Management is actively pursuing financing or other strategic plans but can provide no These condensed consolidated financial statements have been prepared with the assumption that the Company will continue as a going concern and will be able to realize its assets and discharge its liabilities in the normal course of business and do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 1. Principles of Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation. 2. Basis of Presentation The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10Q and Article 8 of Regulation S- X. Accordingly, they do not include all the information and footnotes required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present such interim results. Interim results are not necessarily indicative of the results of operations which may be expected for a full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2018, included in Milestone Scientific's Annual Report on Form 10 -K. 3. Reclassifications Certain reclassifications have been made to the 2018 financial statements to conform to the condensed consolidated 2019 financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported. 4. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates . 5. Revenue Recognition Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third parties. Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no obligation on product sales for any installation, set-up or maintenance, these being the responsibility of the buyer. Milestone Scientific's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty period. Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not consumed by patients and subject to return. The Company relies on historical return rates to estimate returns. In the future, if any of these factors and/or the history of product returns change, adjustments to the allowance for product returns may be required. Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 days from the date of shipment or delivery. Disaggregation of Revenue We operate in two operating segments: dental and medical. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note 10 for revenues by geographical market and operating results by segment for the three and six months ended June 30, 2019 and 2018. 6. Variable Interest Entities A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Because Milestone Scientific has a variable interest in Milestone China, it considered the guidance in ASC 810, “Consolidation” as it relates to determining whether Milestone China is a VIE and, if so, identifying the primary beneficiary. Milestone Scientific would be considered the primary beneficiary of the VIE if it has both of the following characteristics: ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE Milestone Scientific does not have the ability to control the activities that most significantly impact Milestone China's economics and, therefore, the power criterion has not been met. Management placed the most weight on the relationship and significance of activities of Milestone China to the CEO and a group of significant shareholders, including the Milestone China CEO, of Milestone China which have the power to direct the activities that most significantly impact the economic performance of Milestone China. Management has concluded that Milestone Scientific is not the primary beneficiary under ASC 810. Accordingly, Milestone China has not been consolidated into the financial statements of Milestone Scientific and continues to be accounted for under the equity method. See Note 6. 7. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. 8. Accounts Receivable Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 days from invoicing. As of June 30, 2019 and December 31, 2018, accounts receivable (non- related party) was recorded, net of allowance for doubtful accounts of $10,000 . 9. Product Return and Warranty Milestone Scientific generally does not accept non-defective returns from its customers, except for certain customers that can return factory sealed purchases (inventory) that still remain in their locations at the time of termination of their Distributor Agreement. Product returns under warranty are accepted, evaluated and repaired or replaced in accordance with the Warranty Policy. Returns not within the Warranty Policy are evaluated and the customer is charged for the repair. 10. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost ( first -in, first -out method) or net realizable value. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess, slow moving, defective, and obsolete inventory is recorded if required based on past and expected future sales, potential technological obsolescence and product expiration requirements. As of June 30, 2019 and December 31, 2018, inventory was recorded net of a valuation allowance for slow moving and defective inventory of approximately $754,000 and $763,000, respectively. 11. Equity Method Investments Investments in which Milestone Scientific can exercise significant influence, but do not control, are accounted for under the equity method of accounting and are included in the long-term assets on the condensed consolidated balance sheets. Under this method of accounting, Milestone Scientific's share of the net earnings or losses of the investee is presented below the income tax line on the Condensed Consolidated Statements of Operations. 12. Furniture, Fixture and Equipment Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two to seven years. The costs of maintenance and repairs are charged to operations as incurred. 13. Intangible Assets – Patents and Developed Technology Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight--line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are amortized over the remaining estimated useful life of the patent. 14. Impairment of Long-Lived Assets Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company’s impairment review process is based upon an estimate of future undiscounted cash flow. Factors the Company considers that could trigger an impairment review include the following: ● significant under performance relative to expected historical or projected future operating results; ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business; ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. 15. Research and Development Research and development costs, which consist principally of new product development costs payable to third parties, are expensed as incurred. Advance payments for the research are amortized to expense either as services are performed or over the relevant service period using the straight-line method. 16. Income Taxes Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. At June 30, 2019 and December 31, 2018, we had no uncertain tax positions that required recognition in the condensed consolidated financial statements. Milestone Scientific's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the condensed consolidated statements of operations. No interest and penalties are present for periods open. Tax returns for the 2015 , 2016, and 2017 years are subject to audit by federal and state jurisdictions. 17. Basic and diluted net loss per common share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two -class method to calculate basic and diluted net income (loss) per share of common stock, as our Series A Convertible Preferred Stock is a participating security. The two -class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two -class method of computing earnings per share does not apply as our Series A Convertible Preferred Stock does not contractually participate in our losses. The Company did not include any portion of outstanding options, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two -class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. Since Milestone Scientific had net losses for 2019 and 2018, the assumed effects of the exercise of potentially dilutive outstanding stock options, warrants and convertible preferred stock were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options and warrants totaled 5,053,832 and 6,703,553 at June 30, 2019 and December 31, 2018, respectively. 18. Fair Value of Financial Instruments Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one of the following categories: ● Level 1 inputs which are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date. ● Level 2 inputs which are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. ● Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The following table provides the carrying value and fair value of the Company’s financial assets or liabilities (see Note 8 ) measured at fair value on a recurring basis as of June 30, 2019. Carrying Value Level 1 Level 2 Level 3 Derivative Warrants $ 370,747 - - $ 370,747 Shares to be issued-liability 1,045,212 1,045,212 - - Total June 30, 2019 $ 1,415,959 $ 1,045,212 $ - $ 370,747 The following additional disclosures relate to the changes in fair value of the Company’s Level 3 instruments during the six months ended June 30, 2019 : June 30, 2019 Balance at beginning of year $ - Warrants issued in connection with public offering (See Note 8) 376,497 Change in fair value of derivative liability (5,750 ) Balance at end of period $ 370,747 19. Derivative Liability The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that qualify as derivatives and are classified as liabilities on the balance sheet. The Company evaluates all its financial instruments to determine if those instruments or any potential embedded components of those instruments qualify as derivatives that need to be separately accounted for in accordance with FASB ASC 815, “Derivatives and Hedging”. Derivatives satisfying certain criteria are recorded at fair value at issuance and marked-to-market at each balance sheet date with the change in the fair value recorded as income or expense. In addition, upon the occurrence of an event that requires the derivative liability to be reclassified to equity, the derivative liability is revalued to fair value at that date. 20. Stock-Based Compensation Share-based payments to employees, including grants of employee stock options, is recognized in the condensed consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values. 21. Recent Accounting Pronouncements On January 1, 2019, we adopted Accounting Standards Update No. 2016 - 02, Leases (Topic 842 ) (ASU 2016 - 02 ), by ASU 2018 - 11, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. We adopted the new guidance using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. In adopting the new standard, the Company elected to utilize the available package of practical expedients permitted under the transition guidance, which does not require the reassessment of the following: i) whether existing or expired arrangements are or contain a lease, ii) the lease classification of existing or expired leases, and iii) whether previous initial direct costs would qualify for capitalization under the new lease standard. As of the adoption date, the Company identified three operating lease arrangements in which it is a lessee. The adoption of this standard resulted in the recognition of operating lease liabilities and right-of-use assets of $166,292 in the Company’s condensed consolidated balance sheets. The adoption of the standard did not have a material effect on the Company’s statements of operations or statements of cash flows. For information regarding the impact of Topic 842 adoption, see Note 13 – Commitments. On August 28, 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018 - 13, Fair Value Measurement: Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820 ), which changes the fair value measurement disclosure requirements of ASC 820. This ASU removes certain disclosure requirements regarding the amounts and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of transfers between the levels. This ASU also adds disclosure requirements regarding unrealized gains and losses included in Other Comprehensive Income for recurring Level 3 fair value measurements and the range and weighted average of unobservable inputs used in Level 3 fair value measurements. ASU 2018 - 13 is effective for all entities with fiscal years beginning after December 15, 2019, including interim periods therein. Early adoption is permitted for any eliminated or modified disclosures upon issuance of ASU 2018 - 13. The Company is currently evaluating the impact of adopting this standard. In June 2016, the FASB issued a new standard ASU No.2016 - 13, “Financial Instruments – Credit Losses” (Topic 326 ). The new standard is intended to replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. It will be effective for all entities for fiscal years and interim periods, beginning after December 15, 2019. We are currently evaluating the impact of adopting this guidance on our consolidated balance sheet, results of operation and financial condition. In July 2017, the FASB issued a new standard ASU No.2017 - 11, “Earnings Per Share” (Topic 260 ), “Distinguishing Liabilities from Equity” (Topic 480 ), “Derivatives and Hedging” (Topic 815 ). The new standard provides guidance relating to equity-linked instruments that include certain features. It is effective for fiscal years and interim periods, beginning after December 15, 2018. Milestone Scientific adopted this standard in on January 1, 2019. The adoption of this ASU will have immaterial effect on its presentation within the statement of Cash Flows.

Note 4 - Inventories

Note 4 - Inventories	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 Inventories consist of the following: June 30, 2019 December 31, 2018 Dental finished goods, net $ 1,035,167 $ 1,609,000 Medical finished goods, net 153,769 188,133 Component parts and other materials 81,544 123,918 Total inventories $ 1,270,480 $ 1,921,051 At June 30, 2019 December 31, 2018, $452,120 $454,183, $302,073 $309,196,

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE 5 The advances on contracts represent funding of future STA inventory purchases and epidural replacements parts. The balance of the advances as of June 30, 2019 December 31, 2018 $530,000 $649,000

Note 6 - Investment in and Tran

Note 6 - Investment in and Transactions with Unconsolidated Subsidiaries	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 6 Milestone China Ltd. Ownership In June 2014, $1 772 40% Related Party Transactions Milestone China is Milestone Scientific’s exclusive distributor in China. During 2017 2018, 2018 2.8 $200,000 July 2018 November 2018 $1,425,000 December 2018. $950,000 $1.8 $1.25 $1.25 fourth 2018. Milestone Scientific recognized revenue associated with sales to Milestone China and it’s agents of $50,000 $100,000 three six June 30, 2019, three six June 30, 2018, no Gross Profit Deferral Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third 323 40% third At June 30, 2019 December 31, 2018 , $372,200 $421,800, three six June 30, 2019, $58,664 $49,100 third three six June 30, 2018, $78,591 $115,374 third Equity Method Disclosures As June 30,2019 December 31, 2018, $0. June 30, 2019 December 31, 2018, $4,223,449 $3,380,388, The following table includes summarized financial information (unaudited) of Milestone China: June 30, 2019 December 31, 2018 Assets: (unaudited) (unaudited) Current assets $ 13,966,781 $ 10,587,648 Non-current assets 4,974,387 4,603,485 Total assets: $ 18,941,168 $ 15,191,133 Liabilities: Current liabilities $ 23,276,964 $ 17,696,033 Stockholders' deficit (4,335,796 ) (2,504,900 ) Total liabilities and stockholders’ deficit $ 18,941,168 $ 15,191,133 For the three months ended June 30, 2019 For the three months ended June 30, 2018 For the six months ended June 30, 2019 For the six months ended June 30, 2018 (unaudited) (unaudited) (unaudited) (unaudited) Net sales $ 1,149,474 $ 1,328,079 $ 1,753,802 $ 2,085,034 Cost of goods sold 324,300 650,840 559,400 1,098,452 Gross profit 825,174 677,239 1,194,402 986,582 Other expenses (1,423,353 ) (1,119,440 ) (3,302,057 ) (2,371,652 ) Net loss $ (598,179 ) $ (442,201 ) $ (2,107,655 ) $ (1,385,070 )

Note 7 - Patents

Note 7 - Patents	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 7 June 30, 2019 Cost Impairment Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ - $ (969,096 ) $ 408,767 Total $ 1,377,863 $ - $ (969,096 ) $ 408,767 December 31, 2018 Cost Impairment Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ - $ (942,590 ) $ 435,273 Epidural-Apad acquired patents 2,639,647 (1,539,794 ) (1,099,853 ) - Total $ 4,017,510 $ (1,539,794 ) $ (2,042,443 ) $ 435,273 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 20 $13,000 $26,500 three six June 30, 2019, $232,000 $469,000 three six June 30, 2018, During 2018, 2017 not $1.5

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8— PUBLIC OFFERING AND PRIVATE PLACEMENT In February 2019, $2.0 5,715,000 1,428,750 5 $0.50. $198,000 567,400 141,850 Also, in February 2019, $250,000 714,286 178,571 Bp4 Bp4’s 5 $0.50 WARRANTS The following table summarizes information about shares issuable under warrants outstanding at June 30, 2019 : Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2019 1,592,775 $ 2.55 $ 0.48 - Issued 1,749,171 $ 0.50 $ 4.60 - Exercised - - - - Expired or cancelled - - - - Outstanding and exercisable at June 30, 2019 3,341,946 $ 1.48 $ 2.60 - PREFERRED STOCK In May 2014, $10 $3 two million $1.50 $7 7,000 $1,000 $2.545, May 14, 2019. May 14, 2019, $2.545 $1.50 not $3.15 The conversion ratio and anti-dilution adjustment becomes effective if a triggering event occurs such as; issuance of stock dividends or distributions, subdivisions, splits, issuance of stock purchase rights, debt and distributions, cash dividends or distributions, self-tender offers and exchange offers, rights plans and issuance below the conversion price, as defined in the Investment Agreement. Generally, each share of preferred stock entitles the holder to vote together with the holders of Milestone Scientific common stock, as a single class, on all matters submitted for the approval of the holders of Milestone Scientific common stock and has the number of votes equal to the number of shares of our common stock into which they are then convertible. In addition, preferred stock is also entitled to share, pari passu, in any cash dividends declared on Milestone Scientific common stock on as converted basis. On May 14, 2019, $1.17 5,982,906 SHARES TO BE ISSUED As of June 30, 2019 2,185,910 December 31, 2018, 1,908,813 June 30, 2019, 717,456 December 31, 2018, 561,752 SHARES AND WARRANTS IN EXCESS OF AUTHORIZED SHARES As a result of the shares and warrants issued in the public and private offerings as well as other issuances of common stock during 2019, not 4,850,000 2019 2016 The fair value of the warrants is determined using a Black-Scholes option pricing model. The following assumptions were used to value the warrants at the reclassification to liability date: 2016 Warrants 2019 Warrants Expected Term 0.4 years 5 years Volatility 100 % 85 % Dividend yield 0.00 % 0.00 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 2.09 % 2.50 % Weighted average fair value of warrants granted - $ 0.22 Number of shares underlying warrants granted 201,044 1,749,171 As these warrants are liability-classified, they were revalued at June 30, 2019 2016 Warrants 2019 Warrants Expected Term 0.4 years 4.6 years Volatility 100 % 84 % Dividend yield 0.00 % 0.00 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 2.09 % 1.76 % Weighted average fair value of warrants granted $ - $ 0.21 For the three six June 30, 2019 $34,000 $6,000, Additionally, approximately 2,900,000 $0.36 June 30, 2019 ) three six June 30, 2019 $47,000,

Note 9 - Income Taxes

Note 9 - Income Taxes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9 Due to Milestone Scientific's history of operating losses, full valuation allowances have been provided for all of Milestone Scientific's deferred tax assets at June 30, 2019 December 31, 2018. The utilization of Milestone Scientific's net operating losses may 382 may 100%

Note 10 - Segment and Geographi

Note 10 - Segment and Geographic Data	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Product Sales and Significant Customers and Vendors Disclosure [Text Block]	NOTE 10 We conduct our business through two Three months ended June 30 Six months ended June 30 Sales Net Sales: 2019 2018 2019 2018 Dental $ 2,242,751 $ 2,388,898 $ 4,158,259 $ 4,158,003 Medical 15,100 39,600 15,500 76,100 Total net sales $ 2,257,851 $ 2,428,498 $ 4,173,759 $ 4,234,103 Operating Income (Loss): 2019 2018 2019 2018 Dental $ 629,474 $ 723,084 $ 1,121,440 $ 1,080,249 Medical (664,658 ) (846,164 ) (1,156,341 ) (1,554,546 ) Corporate (1,072,647 ) (1,301,607 ) (1,891,114 ) (2,952,043 ) Total operating loss $ (1,107,831 ) $ (1,424,687 ) $ (1,926,015 ) $ (3,426,340 ) Depreciation and Amortization: 2019 2018 2019 2018 Dental $ 3,950 $ 4,103 $ 7,886 $ 8,244 Medical 5,999 2,478 12,170 19,355 Corporate 15,507 238,546 31,445 482,519 Total depreciation and amortization $ 25,456 $ 245,127 $ 51,501 $ 510,118 Income (loss) before taxes and equity in earnings of affiliates: 2019 2018 2019 2018 Dental $ 627,051 $ 725,007 $ 1,120,035 $ 1,084,829 Medical (664,007 ) (846,737 ) (1,156,393 ) (1,555,691 ) Corporate (1,060,788 ) (1,302,787 ) (1,840,553 ) (2,954,345 ) Total loss before taxes and equity in earnings of affiliate $ (1,097,744 ) $ (1,424,517 ) $ (1,876,911 ) $ (3,425,207 ) Total Assets: June 30, 2019 December 31, 2018 Dental $ 5,409,961 $ 5,169,944 Medical 276,787 328,208 Corporate 1,101,541 902,816 Total assets $ 6,788,289 $ 6,400,968 The following table presents information about our operations by geographic area for the three six June 30, 2019 2018. Three months ended June 30, Six months ended June 30, Domestic-US & Canada 2019 2018 2019 2018 Devices $ 146,289 $ 11,505 $ 270,285 $ 132,553 Handpieces 1,030,391 1,158,975 1,819,544 1,927,506 Other 32,463 22,377 49,279 51,228 Total Domestic US & Canada $ 1,209,143 $ 1,192,857 $ 2,139,108 $ 2,111,287 International ROW Devices $ 339,570 $ 367,450 $ 624,915 $ 652,518 Handpieces 631,129 839,194 1,262,839 1,418,021 Other 28,009 28,997 46,897 52,277 Total International-ROW $ 998,708 $ 1,235,641 $ 1,934,651 $ 2,122,816 International-China Devices $ - $ - $ - $ - Handpieces 50,000 - 100,000 - Other - - - - Total International $ 50,000 $ - $ 100,000 $ - Domestic. International Analysis Domestic-US & Canada $ 1,209,143 $ 1,192,857 $ 2,139,108 $ 2,111,287 International -ROW 998,708 1,235,641 1,934,651 2,122,816 International -China 50,000 - 100,000 - Total Product Sales $ 2,257,851 $ 2,428,498 $ 4,173,759 $ 4,234,103

Note 11 - Concentrations

Note 11 - Concentrations	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 11 Milestone Scientific has informal arrangements with third CompuDent CompuMed June 30, 2019 December 31, 2018. For the three six June 30, 2019 52% 50% one three six June 30, 2018 44% 43%, one two $2,850,461 82%, 52% 30% June 30, 2019. $2,555,000, 78% December 31, 2018. June 30, 2019 , $1,817,990 $1,817,990 2018, June 30, 2019 . $1,250,928 June 30, 2019 December 31, 2018, 2018.

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 12 United Systems Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $167,000 $505,600 three six June 30, 2019, $222,000 $574,000 three six June 30, 2018 June 30, 2019 December 31,2018, $1.0 February 2019, 285,714 $0.35 $100,000 June 30, 2019. During 2018 June 30, 2019 December 31, 2018, $342,540 Also, during the year ended December 31, 2018, 1,000 June 2018, 2018, $750,000 $686,365, 2.8 $200,000 July 2018 November 2018 $1,425,000 December 2018. $1.25 6. Milestone China Milestone Scientific owns a 40% 6. Other In August 2016, three $25,000 $50,000 three six June 30, 2019 2018, In January 2017, twelve twelve $20,000 $40,000 three six June 30, 2019 2018, The Director of Clinical Affairs’ royalty fee was approximately $108,000 $199,000 three six June 30, 2019, $116,956 202,481 three six June 30, 2018, $39,000 $78,000 three six June 30, 2019 $39,000 $107,751 three six June 30, 2018 June 30, 2019 December 31, 2018, $410,000 $364,000,

Note 13 - Commitments

Note 13 - Commitments	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 ( 1 Milestone Scientific has informal arrangements with third CompuDent CompuMed January 2018, 1,000 2019. June 30, 2019 $819,725 1,000 $482,680 June 30, 2019 ( 2 Operating Leases In June 2015, 6,851 774 January 31, 2020 $12,522. not not not The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company’s leases do not ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. ● The expected lease terms include noncancelable lease periods. Renewal option periods are not not The components of lease expense as of June 30, 2019 Lease cost Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Operating lease cost $ 39,554 $ 79,109 Total lease cost $ 39,554 $ 79,109 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 79,109 Right-of-use assets obtained in exchange for new operating lease liabilities - Weighted-average remaining lease term - operating leases .06 years Weighted-average discount rate - operating leases 9.2 % Maturities of lease liabilities due under these lease agreements as of June 30, 2019 2019 (excluding the 6 months ended June 30, 2019 ) Operating Leases 2020 $ 79,109 2021 15,976 2022 - 2023 - Thereafter - Total lease payments $ 95,085 Less: interest $ (2,255 ) Total operating lease liabilities as of June 30, 2019 $ 92,830 The Company adopted ASU 2016 02 January 1, 2019 December 31, 2018 Total Less than 1 Year 1-3 Years 3-5 Years Operating Lease Obligations $ 175,557 $ 159,138 $ 16,419 $ - ( 3 The technology underlying the Safety Wand® and CompuFlo CompuDent January 1, 2005. 2.5% 5% third 12

Note 14 - Subsequent Events

Note 14 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 14— In July 2019, 200,000 third In July 2019, 18 150,000

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10Q 8 X. not not may December 31, 2018, 10
Reclassification, Policy [Policy Text Block]	3. Certain reclassifications have been made to the 2018 2019 no
Use of Estimates, Policy [Policy Text Block]	4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, and cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates .
Revenue [Policy Text Block]	5. Under ASC 606, 606, five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are FOB destination, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 10 three six June 30, 2019 2018.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If Milestone Scientific determines that it has operating power and the obligation to absorb losses or receive benefits, Milestone Scientific consolidates the VIE as the primary beneficiary. Milestone Scientific’s involvement constitutes power that is most significant to the entity when it has unconstrained decision-making ability over key operational functions within the entity. Because Milestone Scientific has a variable interest in Milestone China, it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity’s economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE Milestone Scientific does not not not 810. not 6.
Cash and Cash Equivalents, Policy [Policy Text Block]	7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three
Accounts Receivable [Policy Text Block]	8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 June 30, 2019 December 31, 2018, $10,000
Standard Product Warranty, Policy [Policy Text Block]	9. Milestone Scientific generally does not not
Inventory, Policy [Policy Text Block]	10. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first June 30, 2019 December 31, 2018, $754,000 $763,000,
Equity Method Investments [Policy Text Block]	11. Investments in which Milestone Scientific can exercise significant influence, but do not
Property, Plant and Equipment, Policy [Policy Text Block]	12. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	13. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight--line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity are amortized over the remaining estimated useful life of the patent.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	14. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results; ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business; ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.
Research and Development Expense, Policy [Policy Text Block]	15. Research and development costs, which consist principally of new product development costs payable to third
Income Tax, Policy [Policy Text Block]	16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. At June 30, 2019 December 31, 2018, no No 2015 2016, 2017
Earnings Per Share, Policy [Policy Text Block]	17. Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two two two not not The Company did not two not not Since Milestone Scientific had net losses for 2019 2018, not 5,053,832 6,703,553 June 30, 2019 December 31, 2018,
Fair Value of Financial Instruments, Policy [Policy Text Block]	18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may The following table provides the carrying value and fair value of the Company’s financial assets or liabilities (see Note 8 June 30, 2019. Carrying Level 1 Level 2 Level 3 Derivative Warrants $ 370,747 - - $ 370,747 Shares to be issued-liability 1,045,212 1,045,212 - - Total June 30, 2019 $ 1,415,959 $ 1,045,212 $ - $ 370,747 The following additional disclosures relate to the changes in fair value of the Company’s Level 3 six June 30, 2019 : June 30, 2019 Balance at beginning of year $ - Warrants issued in connection with public offering (See Note 8) 376,497 Change in fair value of derivative liability (5,750 ) Balance at end of period $ 370,747
Derivatives, Policy [Policy Text Block]	19. The Company does not 815,
Share-based Payment Arrangement [Policy Text Block]	20. Share-based payments to employees, including grants of employee stock options, is recognized in the condensed consolidated statements of operations over the service period, as an operating expense, based on the grant-date fair values.
New Accounting Pronouncements, Policy [Policy Text Block]	21. On January 1, 2019, No. 2016 02, 842 2016 02 2018 11, 840, not not three $166,292 not 842 13 On August 28, 2018, 2018 13, 820 820. 1 2 3 3 2018 13 December 15, 2019, 2018 13. In June 2016, No.2016 13, 326 December 15, 2019. In July 2017, No.2017 11, 260 480 815 December 15, 2018. January 1, 2019.

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Carrying Level 1 Level 2 Level 3 Derivative Warrants $ 370,747 - - $ 370,747 Shares to be issued-liability 1,045,212 1,045,212 - - Total June 30, 2019 $ 1,415,959 $ 1,045,212 $ - $ 370,747
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	June 30, 2019 Balance at beginning of year $ - Warrants issued in connection with public offering (See Note 8) 376,497 Change in fair value of derivative liability (5,750 ) Balance at end of period $ 370,747

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Inventories consist of the following: June 30, 2019 December 31, 2018 Dental finished goods, net $ 1,035,167 $ 1,609,000 Medical finished goods, net 153,769 188,133 Component parts and other materials 81,544 123,918 Total inventories $ 1,270,480 $ 1,921,051

Note 6 - Investment in and Tr_2

Note 6 - Investment in and Transactions with Unconsolidated Subsidiaries (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Equity Method Investments [Table Text Block]	June 30, 2019 December 31, 2018 Assets: (unaudited) (unaudited) Current assets $ 13,966,781 $ 10,587,648 Non-current assets 4,974,387 4,603,485 Total assets: $ 18,941,168 $ 15,191,133 Liabilities: Current liabilities $ 23,276,964 $ 17,696,033 Stockholders' deficit (4,335,796 ) (2,504,900 ) Total liabilities and stockholders’ deficit $ 18,941,168 $ 15,191,133 For the three months ended June 30, 2019 For the three months ended June 30, 2018 For the six months ended June 30, 2019 For the six months ended June 30, 2018 (unaudited) (unaudited) (unaudited) (unaudited) Net sales $ 1,149,474 $ 1,328,079 $ 1,753,802 $ 2,085,034 Cost of goods sold 324,300 650,840 559,400 1,098,452 Gross profit 825,174 677,239 1,194,402 986,582 Other expenses (1,423,353 ) (1,119,440 ) (3,302,057 ) (2,371,652 ) Net loss $ (598,179 ) $ (442,201 ) $ (2,107,655 ) $ (1,385,070 )

Note 7 - Patents (Tables)

Note 7 - Patents (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2019 Cost Impairment Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ - $ (969,096 ) $ 408,767 Total $ 1,377,863 $ - $ (969,096 ) $ 408,767 December 31, 2018 Cost Impairment Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ - $ (942,590 ) $ 435,273 Epidural-Apad acquired patents 2,639,647 (1,539,794 ) (1,099,853 ) - Total $ 4,017,510 $ (1,539,794 ) $ (2,042,443 ) $ 435,273

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2019 1,592,775 $ 2.55 $ 0.48 - Issued 1,749,171 $ 0.50 $ 4.60 - Exercised - - - - Expired or cancelled - - - - Outstanding and exercisable at June 30, 2019 3,341,946 $ 1.48 $ 2.60 -
Schedule of Warrant or Right Outstanding, Valuation Assumptions [Table Text Block]	2016 Warrants 2019 Warrants Expected Term 0.4 years 5 years Volatility 100 % 85 % Dividend yield 0.00 % 0.00 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 2.09 % 2.50 % Weighted average fair value of warrants granted - $ 0.22 Number of shares underlying warrants granted 201,044 1,749,171
Warrant Liabilities [Member]
Notes Tables
Schedule of Warrant or Right Outstanding, Valuation Assumptions [Table Text Block]	2016 Warrants 2019 Warrants Expected Term 0.4 years 4.6 years Volatility 100 % 84 % Dividend yield 0.00 % 0.00 % Exercise Price $ 2.55 $ 0.50 Risk-free interest rate 2.09 % 1.76 % Weighted average fair value of warrants granted $ - $ 0.21

Note 10 - Segment and Geograp_2

Note 10 - Segment and Geographic Data (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three months ended June 30 Six months ended June 30 Sales Net Sales: 2019 2018 2019 2018 Dental $ 2,242,751 $ 2,388,898 $ 4,158,259 $ 4,158,003 Medical 15,100 39,600 15,500 76,100 Total net sales $ 2,257,851 $ 2,428,498 $ 4,173,759 $ 4,234,103 Operating Income (Loss): 2019 2018 2019 2018 Dental $ 629,474 $ 723,084 $ 1,121,440 $ 1,080,249 Medical (664,658 ) (846,164 ) (1,156,341 ) (1,554,546 ) Corporate (1,072,647 ) (1,301,607 ) (1,891,114 ) (2,952,043 ) Total operating loss $ (1,107,831 ) $ (1,424,687 ) $ (1,926,015 ) $ (3,426,340 ) Depreciation and Amortization: 2019 2018 2019 2018 Dental $ 3,950 $ 4,103 $ 7,886 $ 8,244 Medical 5,999 2,478 12,170 19,355 Corporate 15,507 238,546 31,445 482,519 Total depreciation and amortization $ 25,456 $ 245,127 $ 51,501 $ 510,118 Income (loss) before taxes and equity in earnings of affiliates: 2019 2018 2019 2018 Dental $ 627,051 $ 725,007 $ 1,120,035 $ 1,084,829 Medical (664,007 ) (846,737 ) (1,156,393 ) (1,555,691 ) Corporate (1,060,788 ) (1,302,787 ) (1,840,553 ) (2,954,345 ) Total loss before taxes and equity in earnings of affiliate $ (1,097,744 ) $ (1,424,517 ) $ (1,876,911 ) $ (3,425,207 ) Total Assets: June 30, 2019 December 31, 2018 Dental $ 5,409,961 $ 5,169,944 Medical 276,787 328,208 Corporate 1,101,541 902,816 Total assets $ 6,788,289 $ 6,400,968
Sales by Product and by Geographical Region [Table Text Block]	Three months ended June 30, Six months ended June 30, Domestic-US & Canada 2019 2018 2019 2018 Devices $ 146,289 $ 11,505 $ 270,285 $ 132,553 Handpieces 1,030,391 1,158,975 1,819,544 1,927,506 Other 32,463 22,377 49,279 51,228 Total Domestic US & Canada $ 1,209,143 $ 1,192,857 $ 2,139,108 $ 2,111,287 International ROW Devices $ 339,570 $ 367,450 $ 624,915 $ 652,518 Handpieces 631,129 839,194 1,262,839 1,418,021 Other 28,009 28,997 46,897 52,277 Total International-ROW $ 998,708 $ 1,235,641 $ 1,934,651 $ 2,122,816 International-China Devices $ - $ - $ - $ - Handpieces 50,000 - 100,000 - Other - - - - Total International $ 50,000 $ - $ 100,000 $ - Domestic. International Analysis Domestic-US & Canada $ 1,209,143 $ 1,192,857 $ 2,139,108 $ 2,111,287 International -ROW 998,708 1,235,641 1,934,651 2,122,816 International -China 50,000 - 100,000 - Total Product Sales $ 2,257,851 $ 2,428,498 $ 4,173,759 $ 4,234,103

Note 13 - Commitments (Tables)

Note 13 - Commitments (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lease, Cost and Other Information [Table Text Block]	Lease cost Three Months Ended June 30, 2019 Six Months Ended June 30, 2019 Operating lease cost $ 39,554 $ 79,109 Total lease cost $ 39,554 $ 79,109 Other information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 79,109 Right-of-use assets obtained in exchange for new operating lease liabilities - Weighted-average remaining lease term - operating leases .06 years Weighted-average discount rate - operating leases 9.2 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2019 (excluding the 6 months ended June 30, 2019 ) Operating Leases 2020 $ 79,109 2021 15,976 2022 - 2023 - Thereafter - Total lease payments $ 95,085 Less: interest $ (2,255 ) Total operating lease liabilities as of June 30, 2019 $ 92,830
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Total Less than 1 Year 1-3 Years 3-5 Years Operating Lease Obligations $ 175,557 $ 159,138 $ 16,419 $ -

Note 1 - Organization and Bus_2

Note 1 - Organization and Business (Details Textual)	1 Months Ended			6 Months Ended
	Mar. 31, 2019USD ($)shares	Feb. 28, 2019USD ($)$ / sharesshares	May 31, 2014USD ($)shares	Jun. 30, 2019USD ($)$ / shares	Jun. 30, 2018USD ($)	Dec. 31, 2018$ / shares
Number of Countries in which Entity Operates				60
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.48		$ 2.55
Proceeds from Issuance of Private Placement | $		$ 250,000	$ 10,000,000	$ 250,000
Warrants, Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,428,750
Warrants and Rights Outstanding, Term		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50
Underwrite Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	141,850	141,850
Warrants, Private Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		178,571
Warrants and Rights Outstanding, Term		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.50
Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total | $		$ 2,000,000
Stock Issued During Period, Shares, New Issues		5,715,000
Proceeds from Stock Options Exercised | $	$ 198,000	$ 198,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	567,400	567,400
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		714,286	2,000,000

Note 2 - Going Concern and Li_2

Note 2 - Going Concern and Liquidity (Details Textual) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 2,337,593	$ 743,429	$ 865,654	$ 2,636,956

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)shares	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)shares	Jan. 01, 2019USD ($)
Number of Operating Segments	2
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 10,000		$ 10,000
Inventory Valuation Reserves, Ending Balance	754,000		763,000
Unrecognized Tax Benefits, Ending Balance	0		0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	$ 0	$ 0
Open Tax Year	2015 2016 2017
Operating Lease, Right-of-Use Asset	$ 92,830			$ 166,292
Operating Lease, Liability, Total	$ 92,830			$ 166,292
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares	5,053,832		6,703,553
Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Polices - Fair Value of Financial Instruments (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Derivative liability	$ 1,418,863
Fair Value, Recurring [Member]
Derivative liability	1,415,959
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liability	1,045,212
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liability	370,747
Derivative Warrants [Member] | Fair Value, Recurring [Member]
Derivative liability	370,747
Derivative Warrants [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liability
Derivative Warrants [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liability
Derivative Warrants [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liability	370,747
Stock To be Issued [Member] | Fair Value, Recurring [Member]
Derivative liability	1,045,212
Stock To be Issued [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liability	1,045,212
Stock To be Issued [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liability
Stock To be Issued [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liability

Note 3 - Summary of Significa_5

Note 3 - Summary of Significant Accounting Policies - Fair Value of Level 3 Instruments (Details) - Derivative Financial Instruments, Liabilities [Member]	6 Months Ended
	Jun. 30, 2019USD ($)
Balance at beginning of year
Warrants issued in connection with public offering (See Note 8)	376,497
Change in fair value of derivative liability	5,750
Balance at end of period	$ 370,747

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Inventory Valuation Reserves, Ending Balance	$ 754,000	$ 763,000
Slow Moving Medical Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance	452,120	454,183
Slow Moving Dental Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance	$ 302,073	$ 309,196

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Component parts and other materials	$ 81,544	$ 123,918
Total inventories	1,270,480	1,921,051
Dental Segment [Member]
Finished goods, net	1,035,167	1,609,000
Medical Segment [Member]
Finished goods, net	$ 153,769	$ 188,133

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts (Details Textual) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Advances on Inventory Purchases	$ 530,114	$ 648,783

Note 6 - Investment in and Tr_3

Note 6 - Investment in and Transactions with Unconsolidated Subsidiaries (Details Textual)	1 Months Ended		3 Months Ended		5 Months Ended	6 Months Ended			12 Months Ended
	Dec. 31, 2018USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Nov. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 10,000		$ 10,000			$ 10,000	$ 10,000		$ 10,000
Income (Loss) from Equity Method Investments, Total			58,664	$ 78,591		49,100		$ 115,374
Milestone China [Member]
Equity Method Investments	0	$ 1,000,000	0			0	0		0
Long-term Purchase Commitment, Minimum Quantity Required		772
Equity Method Investment, Ownership Percentage		40.00%
Financing Receivable, after Allowance for Credit Loss, Total	2,800,000						2,800,000		2,800,000
Account Receivables, Related Party, Monthly Payment					$ 200,000
Accounts Receivable, Related Party, Balloon Payment to be Paid	1,425,000
Proceeds from Collection of Finance Receivables							950,000
Contract With Customer Liability Before Reserve Adjustment	1,800,000						1,800,000		1,800,000
Capitalized Contract Before Reserve Adjustment	1,250,000						1,250,000		1,250,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance			1,250,000			1,250,000
Contract with Customer, Liability, Revenue Recognized			50,000	0		$ 100,000		0
Equity Method Investment, Deferred Intercompany Profit (Loss), Percentage						40.00%
Income (Loss) from Equity Method Investments, Total			58,664	$ 78,591		$ 49,100		$ 115,374
Cost-method Investments, Realized Losses						4,223,449			3,380,388
Milestone China [Member] | Accounts Receivable from Related Parties [Member]
Equity Method Investment, Deferred Intercompany Profit (Loss)	$ 421,800		$ 372,200			$ 372,200	$ 421,800		$ 421,800

Note 6 - Investment in and Tr_4

Note 6 - Investment in and Transactions with Unconsolidated Subsidiaries - Summarized Financial Information (Unaudited) of Milestone China (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Total assets:	$ 18,941,168		$ 18,941,168		$ 15,191,133
Current liabilities	23,276,964		23,276,964		17,696,033
Stockholders' deficit	(4,335,796)		(4,335,796)		(2,504,900)
Total liabilities and stockholders’ deficit	18,941,168		18,941,168		15,191,133
Net sales	1,149,474	$ 1,328,079	1,753,802	$ 2,085,034
Cost of goods sold	324,300	650,840	559,400	1,098,452
Gross profit	825,174	677,239	1,194,402	986,582
Other expenses	(1,423,353)	(1,119,440)	(3,302,057)	(2,371,652)
Net loss	(598,179)	$ (442,201)	(2,107,655)	$ (1,385,070)
Milestone China [Member]
Current assets	13,966,781		13,966,781		10,587,648
Non-current assets	$ 4,974,387		$ 4,974,387		$ 4,603,485

Note 7 - Patents (Details Textu

Note 7 - Patents (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Amortization of Intangible Assets, Total			$ 26,506	$ 469,356
Impairment of Intangible Assets, Finite-lived					$ 1,500,000
Patents [Member]
Amortization of Intangible Assets, Total	$ 13,000	$ 232,000	$ 26,500	$ 469,000
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life			3 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life			20 years

Note 7 - Patents - Summary of P

Note 7 - Patents - Summary of Patents (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Patents, cost	$ 1,377,863	$ 4,017,510
Patents, impairment		(1,539,794)
Patents, accumulated amortization	(969,096)	(2,042,443)
Patents, net	408,767	435,273
Foundation Intellectual Property Patents [Member]
Patents, cost	1,377,863	1,377,863
Patents, impairment
Patents, accumulated amortization	(969,096)	(942,590)
Patents, net	$ 408,767	435,273
Epidural-Apad Patents [Member]
Patents, cost		2,639,647
Patents, impairment		(1,539,794)
Patents, accumulated amortization		(1,099,853)
Patents, net

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	May 14, 2019	Mar. 31, 2019	Feb. 28, 2019	May 31, 2014	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 1.48	$ 1.48		$ 2.55
Proceeds from Issuance of Private Placement			$ 250,000	$ 10,000,000		$ 250,000
Proceeds from Issuance of Common Stock						$ 1,974,547
Equity Securities Issued					4,850,000	4,850,000
Common Stock, Shares, To be Issued					2,900,000	2,900,000
Share Price					$ 0.36	$ 0.36
Gain (Loss) on Liability Classified Shares to Be Issued						$ 47,000
Warrant [Member]
Derivative, Gain (Loss) on Derivative, Net, Total					$ (34,000)	$ 6,000
Chief Executive Officer, Chief Financial Officer and Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance					2,185,910	2,185,910		1,908,813
Non-Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance					717,456	717,456		561,752
Preferred Stock Converted to Common Stock [Member]
Conversion of Stock, Conversion Price	$ 1.17
Conversion of Stock, Shares Issued	5,982,906
Warrants, Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,428,750
Warrants and Rights Outstanding, Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50
Underwrite Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		141,850	141,850
Warrants, Private Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			178,571
Warrants and Rights Outstanding, Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50
Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total			$ 2,000,000
Stock Issued During Period, Shares, New Issues			5,715,000
Proceeds from Stock Options Exercised		$ 198,000	$ 198,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		567,400	567,400
Private Placement [Member]
Stock Issued During Period, Shares, New Issues			714,286	2,000,000
Proceeds from Issuance of Common Stock				$ 3,000,000
Shares Issued, Price Per Share				$ 1.50
Proceeds from Issuance of Convertible Preferred Stock				$ 7,000,000
Private Placement [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues				7,000
Shares Issued, Price Per Share				$ 1,000
Preferred Stock, Redemption Price Per Share				2.545
Private Placement [Member] | Series A Convertible Preferred Stock [Member] | Conversion Price if Common Stock Not Trade at 3.15 [Member]
Preferred Stock, Redemption Price Per Share				1.50
Convertible Preferred Stock, Shares Price Trigger				$ 3.15

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Outstanding, number of shares (in shares)	1,592,775
Outstanding, weighted average exercise price (in dollars per share)	$ 2.55
Outstanding, weighted average remaining life (Year)	2 years 219 days	175 days
Issued, number of shares (in shares)	1,749,171
Issued, weighted average exercise price (in dollars per share)	$ 0.50
Issued, weighted average remaining life (Year)	4 years 219 days
Exercised, number of shares (in shares)
Exercised, weighted average exercise price (in dollars per share)
Expired or cancelled, number of shares (in shares)
Expired or cancelled, weighted average exercise price (in dollars per share)
Outstanding , number of shares (in shares)	3,341,946
Outstanding , weighted average exercise price (in dollars per share)	$ 1.48

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Assumptions Used to Value Warrants at Grant Date (Details)	Jun. 30, 2019$ / sharesyr
Measurement Input, Expected Term [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year) | yr	0.4
Measurement Input, Expected Term [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year) | yr	5
Measurement Input, Price Volatility [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	1
Measurement Input, Price Volatility [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.85
Measurement Input, Expected Dividend Rate [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0
Measurement Input, Exercise Price [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	2.55
Measurement Input, Exercise Price [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.5
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	0.0209
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.025
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.22
Measurement Input, Number of Shares Granted [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	201,044
Measurement Input, Number of Shares Granted [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	1,749,171

Note 8 - Stockholders' Equity_4

Note 8 - Stockholders' Equity - Assumption Used to Value Liability Classified Warrants at Grant Date (Details)	Jun. 30, 2019$ / sharesyr
Measurement Input, Expected Term [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year) | yr	0.4
Measurement Input, Expected Term [Member] | The 2016 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year) | yr	0.4
Measurement Input, Expected Term [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year) | yr	5
Measurement Input, Expected Term [Member] | The 2019 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year) | yr	4.6
Measurement Input, Price Volatility [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	1
Measurement Input, Price Volatility [Member] | The 2016 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	1
Measurement Input, Price Volatility [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.85
Measurement Input, Price Volatility [Member] | The 2019 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0.84
Measurement Input, Expected Dividend Rate [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	0
Measurement Input, Expected Dividend Rate [Member] | The 2016 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0
Measurement Input, Exercise Price [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	2.55
Measurement Input, Exercise Price [Member] | The 2016 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	2.55
Measurement Input, Exercise Price [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.5
Measurement Input, Exercise Price [Member] | The 2019 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0.5
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)	0.0209
Measurement Input, Risk Free Interest Rate [Member] | The 2016 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0.0209
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.025
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0.0176
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2016 Warrants [Member]
Warrants, measurement input (Year)
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2016 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2019 Warrants [Member]
Warrants, measurement input (Year)	0.22
Measurement Input, Weighted Average of Shares Granted, Fair Value [Member] | The 2019 Warrants [Member] | Warrant Liabilities [Member]
Warrants, measurement input (Year)	0.21

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual)	6 Months Ended
	Jun. 30, 2019
Percentage of Valuation Allowance	100.00%

Note 10 - Segment and Geograp_3

Note 10 - Segment and Geographic Data (Details Textual)	6 Months Ended
	Jun. 30, 2019
Number of Reportable Segments	2

Note 10 - Segment and Geograp_4

Note 10 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Product sales, net	$ 2,257,851	$ 2,428,498	$ 4,173,759	$ 4,234,103
Operating Income (Loss)	(1,107,831)	(1,424,687)	(1,926,015)	(3,426,340)
Depreciation and Amortization	25,456	245,127	51,501	510,118
Income (loss) before taxes and equity in earnings of affiliates	(1,097,744)	(1,424,517)	(1,876,911)	(3,425,207)
Assets	6,788,289		6,788,289		$ 6,400,968
Corporate, Non-Segment [Member]
Operating Income (Loss)	(1,072,647)	(1,301,607)	(1,891,114)	(2,952,043)
Depreciation and Amortization	15,507	238,546	31,445	482,519
Income (loss) before taxes and equity in earnings of affiliates	(1,060,788)	(1,302,787)	(1,840,553)	(2,954,345)
Assets	1,101,541		1,101,541		902,816
Dental Segment [Member] | Operating Segments [Member]
Product sales, net	2,242,751	2,388,898	4,158,259	4,158,003
Operating Income (Loss)	629,474	723,084	1,121,440	1,080,249
Depreciation and Amortization	3,950	4,103	7,886	8,244
Income (loss) before taxes and equity in earnings of affiliates	627,051	725,007	1,120,035	1,084,829
Assets	5,409,961		5,409,961		5,169,944
Medical Segment [Member] | Operating Segments [Member]
Product sales, net	15,100	39,600	15,500	76,100
Operating Income (Loss)	(664,658)	(846,164)	(1,156,341)	(1,554,546)
Depreciation and Amortization	5,999	2,478	12,170	19,355
Income (loss) before taxes and equity in earnings of affiliates	(664,007)	$ (846,737)	(1,156,393)	$ (1,555,691)
Assets	$ 276,787		$ 276,787		$ 328,208

Note 10 - Segment and Geograp_5

Note 10 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Product sales, net	$ 2,257,851	$ 2,428,498	$ 4,173,759	$ 4,234,103
Domestic [Member]
Product sales, net	1,209,143	1,192,857	2,139,108	2,111,287
Domestic [Member] | Devices [Member]
Product sales, net	146,289	11,505	270,285	132,553
Domestic [Member] | Handpieces [Member]
Product sales, net	1,030,391	1,158,975	1,819,544	1,927,506
Domestic [Member] | Other Products [Member]
Product sales, net	32,463	22,377	49,279	51,228
Rest of World [Member]
Product sales, net	998,708	1,235,641	1,934,651	2,122,816
Rest of World [Member] | Devices [Member]
Product sales, net	339,570	367,450	624,915	652,518
Rest of World [Member] | Handpieces [Member]
Product sales, net	631,129	839,194	1,262,839	1,418,021
Rest of World [Member] | Other Products [Member]
Product sales, net	28,009	28,997	46,897	52,277
CHINA
Product sales, net	50,000		100,000
CHINA | Devices [Member]
Product sales, net
CHINA | Handpieces [Member]
Product sales, net	50,000		100,000
CHINA | Other Products [Member]
Product sales, net

Note 11 - Concentrations (Detai

Note 11 - Concentrations (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018	Jun. 30, 2019USD ($)	Jun. 30, 2018	Dec. 31, 2018USD ($)
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 10,000		$ 10,000		$ 10,000
Milestone China [Member]
Accounts Receivable, before Allowance for Credit Loss	1,817,990		1,817,990
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 1,817,990		$ 1,817,990
Accounts Receivable, Credit Loss Expense (Reversal)					$ 1,250,928
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage		44.00%		43.00%
Number of Customers	1	1	1	1
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Concentration Risk, Percentage	52.00%	52.00%	50.00%	50.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Customers			2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage			82.00%
Accounts Receivable, before Allowance for Credit Loss	$ 2,850,461		$ 2,850,461
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Concentration Risk, Percentage			52.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Concentration Risk, Percentage			30.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Milestone China [Member]
Concentration Risk, Percentage					78.00%
Accounts Receivable, before Allowance for Credit Loss					$ 2,555,000

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended				3 Months Ended		5 Months Ended	6 Months Ended		12 Months Ended
	Feb. 28, 2019	Dec. 31, 2018	Jan. 31, 2017	Aug. 31, 2016	Jun. 30, 2019	Jun. 30, 2018	Nov. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Jun. 30, 2014
Director of Clinical Affairs [Member]
Royalty Expense					$ 108,000	$ 116,956		$ 199,000	$ 202,481
Professional Fees					39,000	39,000		78,000	107,751
Accounts Payable, Related Parties		$ 364,000			410,000			410,000		$ 364,000
Milestone China [Member]
Financing Receivable, after Allowance for Credit Loss, Total		2,800,000								2,800,000
Account Receivables, Related Party, Monthly Payment							$ 200,000
Accounts Receivable, Related Party, Balloon Payment to be Paid		1,425,000
Inventory Adjustments, Total					1,250,000			1,250,000
Equity Method Investment, Ownership Percentage											40.00%
United Systems [Member]
Capitalized Contract Cost, Net, Total		686,365								686,365
Wand Dental Inc [Member]
Deferred Revenue, Current, Total		342,540			342,540			342,540		342,540
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party					167,000	222,000		505,600	574,000
Due to Related Parties, Total		$ 1,000,000			1,000,000			1,000,000		1,000,000
Consulting Services [Member]
Consulting Services Agreement, Term				3 years
Related Party Transaction, Expenses from Transactions with Related Party					25,000	25,000		50,000	50,000
Consulting Services [Member] | United Systems [Member]
Stock Issued During Period, Shares, Issued for Services	285,714
Shares Issued, Price Per Share	$ 0.35
Stock Issued During Period, Value, Issued for Services	$ 100,000
Distributor Agreement to Milestone China [Member] | United Systems [Member]
Revenue from Related Parties										$ 750,000
Consultant [Member] | Innovest S.p.A. [Member]
Consulting Services Agreement, Term			1 year
Related Party Transaction, Expenses from Transactions with Related Party					$ 20,000	$ 20,000		$ 40,000	$ 40,000
Consulting Services Agreement, Renewal Term			1 year

Note 13 - Commitments (Details

Note 13 - Commitments (Details Textual)	Jan. 01, 2005	Jun. 30, 2015USD ($)ft²	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Advances on Inventory Purchases			$ 530,114	$ 648,783
Operating Leases, Monthly Rent Expense		$ 12,522
Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology	2.50%
Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology	5.00%
Office Lease for Headquarter in Livingston, New Jersey [Member]
Area of Real Estate Property | ft²		6,851
Area of Rentable Space | ft²		774
Purchase Commitment for Devices [Member]
Purchase Commitment Number Of Units			1,000
Purchase Commitment, Remaining Minimum Amount Committed			$ 819,725
Advances on Inventory Purchases			$ 482,680

Note 13 - Commitments - Lease E

Note 13 - Commitments - Lease Expense (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)
Operating lease cost	$ 39,554	$ 79,109
Total lease cost	$ 39,554	79,109
Operating cash flows from operating leases		79,109
Right-of-use assets obtained in exchange for new operating lease liabilities
Weighted-average remaining lease term - operating leases (Year)	21 days	21 days
Weighted-average discount rate - operating leases	9.20%	9.20%

Note 13 - Commitments - Maturit

Note 13 - Commitments - Maturities of Lease Liabilities (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019
2020	$ 79,109
2021	15,976
2022
2023
Thereafter
Total lease payments	95,085
Less: interest	(2,255)
Operating Lease, Liability, Total	$ 92,830	$ 166,292

Note 13 - Commitments - Future

Note 13 - Commitments - Future Minimum Lease Payments and Operating Lease Commitments (Details)	Dec. 31, 2018USD ($)
Operating Lease Obligations	$ 175,557
Operating Lease Obligations, less than 1 year	159,138
Operating Lease Obligations, 1-3 years	16,419
Operating Lease Obligations, 3-5 years

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Restricted Stock [Member]	Jul. 31, 2019shares
Third Party Advisor [Member]
Common Stock, Capital Shares Reserved for Future Issuance	200,000
Investor Relations Consultant [Member]
Common Stock, Capital Shares Reserved for Future Issuance	150,000